Ampio (AMPE) Submits Pre-IND Package on Zertane to FDA

Ampio Pharmaceuticals, Inc. (Nasdaq: AMPE) has submitted to the FDA a pre IND package on Zertane, its on-demand premature ejaculation drug, for a meeting and discussion on the approval path under the 505(b) 2 regulation/registration requirement in the US.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Inhibikase Therapeutics (IKT) Issues Letter to Shareholders and Provides Update on Development Programs
• Kingstone (KINS) Files $50M Mixed Shelf
• Barinthus Biotherapeutics (BRNS) Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus (HPV) Infections